Genmab — September 2024
-
Enhancing Fc-mediated effector functions of monoclonal antibodies: The example of HexaBodies https://onlinelibrary.wiley.com/doi/10.1111/imr.13394?af=R [The review will summarize the development, preclinical, and clinical testing of several HexaBodies designed for the treatment of B-cell malignancies, as well as the potential use of the HexaBody technology beyond Fc-mediated effector functions.]
-
not sure anyone saw this yet for congress presentations
https://www.genmabmedicalaffairs.com/congress -
for example Rinatabart Sesutecan
(Rina-S) at ESMO https://www.genmabmedicalaffairs.com/sfsites/c/sfc/servlet.shepherd/document/download/069Po00000IYCh9IAH -
Godmorgen
-
Godmorgen. Jeg aner en smule bred optimisme ud fra de sene kommentarer her i chatten i aftes?
-
Så kan løfteraketterne snart starte deres indledende tests
-
Det ville være direkte ufornuftigt af JNJ ikke at vælge ERZO-optionen, hvis dataene er favorable. Det koster kun 200 millioner, hvilket er en lille sum for JNJ. Hvis dataene er positive, kan ERZO repræsentere en risiko for JNJ, hvis en anden stor medicinalvirksomhed, som f.eks. AbbVie, beslutter sig for at købe 50 % af ERZO for de samme 200 millioner. Jeg tvivler på, at JNJ vil tage den risiko, når de kan eliminere den ved at betale 200 millioner. Hvis dataene derimod er meget dårlige, er situat
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind